Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

University of Toronto, Department of Pharmaceutical Sciences, Toronto, ON, Canada M5S 2S2.
BMJ (online) (Impact Factor: 16.38). 11/2005; 331(7526):1169. DOI: 10.1136/bmj.38623.768588.47
Source: PubMed

ABSTRACT To quantify and compare potential benefits (subjective reports of sleep variables) and risks (adverse events and morning-after psychomotor impairment) of short term treatment with sedative hypnotics in older people with insomnia.
Medline, Embase, the Cochrane clinical trials database, PubMed, and PsychLit, 1966 to 2003; bibliographies of published reviews and meta-analyses; manufacturers of newer sedative hypnotics (zaleplon, zolpidem, zopiclone) regarding unpublished studies.
Randomised controlled trials of any pharmacological treatment for insomnia for at least five consecutive nights in people aged 60 or over with insomnia and otherwise free of psychiatric or psychological disorders.
24 studies (involving 2417 participants) with extractable data met inclusion and exclusion criteria. Sleep quality improved (effect size 0.14, P < 0.05), total sleep time increased (mean 25.2 minutes, P < 0.001), and the number of night time awakenings decreased (0.63, P < 0.001) with sedative use compared with placebo. Adverse events were more common with sedatives than with placebo: adverse cognitive events were 4.78 times more common (95% confidence interval 1.47 to 15.47, P < 0.01); adverse psychomotor events were 2.61 times more common (1.12 to 6.09, P > 0.05), and reports of daytime fatigue were 3.82 times more common (1.88 to 7.80, P < 0.001) in people using any sedative compared with placebo.
Improvements in sleep with sedative use are statistically significant, but the magnitude of effect is small. The increased risk of adverse events is statistically significant and potentially clinically relevant in older people at risk of falls and cognitive impairment. In people over 60, the benefits of these drugs may not justify the increased risk, particularly if the patient has additional risk factors for cognitive or psychomotor adverse events.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anxiety is a common symptom among patients with cognitive impairment. The presence of anxiety is correlated with poorer outcomes; despite this, there is limited research on anxiety related to neurodegenerative disorder. In this article, we discuss the prevalence of anxiety and factors involved in the etiology of anxiety in patients with diagnosed neurodegenerative disorders and related states of cognitive impairment as well as the evidence for currently available methods of evaluating and treating these symptoms. Specific treatments are highlighted in light of current evidence, followed by a discussion of the difficulties inherent in the study and treatment of anxiety in this population.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION Insomnia is a commonly reported clinical symptom. The annual prevalence of insomnia symptoms has been reported to range from 35–50% of the population, 1 including cases of in-somnia disorders occurring at 10–22%, 2,3 although the exact frequency depends on the diag-nostic criteria applied. The prevalence of insomnia symptoms in Korea was reported to be 17– 23%, 4,5 including Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis in 5% of the patients. 4 Insomnia is predictive of psychiatric disorders, including de-pression, anxiety disorders, and alcohol or drug abuse, and is also associated with physical function and quality of life. The prevalence of insomnia is greater in the elderly population. 4,5 Insomnia shows a female predisposition which is consistent and progressive with age, becom-ing more prevalent in the elderly. 6 Additionally, it has been reported that chronic benzodiaze-pine or hypnotic drug users are most often elderly. 7,8 The pharmacokinetics and clearance of hypnotic drugs may be altered in elderly individuals compared to younger individuals. It is well known that benzodiazepine, which has a long half-life, may be associated with an in-creased incidence of adverse events, such as confusion or falling down, among the elderly. 9-11 Several hypnotic drugs have been approved by the Korean Food and Drug Administration (KFDA). Physicians can also prescribe many hypnotic medications for insomnia without KFDA indication, including antipsychotics, benzodiazepine, and sedative antidepressants such as am-itriptyline and trazodone antihistamine. Many people who suffer from sleep problems do not Correspondence Background and ObjectiveaaThis study aimed to characterize patterns of hypnotic drug prescription based on age and gender using data from the Health Insurance Review and Assessment Service-National Patients Sample (HIRA-NPS) of South Korea.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims The objective of the study was to provide observational clinical data on psychotropic drugs and especially hypnotics used in older people with mental illness. Method This was an observational, single-centre, one-week prevalence study of psychiatric symptoms, disorders and psychotropic/hypnotic drug use in older people with mental illness cared for by the South West people Yorkshire Mental Health NHS Trust (Wakefield Locality), UK. Results A total of 593/660 older patients with mental illness (mean±SD age, 76±8.1 years) were assessed). 44.5% had dementia (excluding vascular dementia) and 33.7% had a mood disorder. Of the total, 20.4% did not receive CNS active medication and 46.2% of patients were prescribed an antidepressant. In total 130 (21.9%) of patients were prescribed an hypnotic and these were more likely to be prescribed to patients with depression (35%) compared with other diagnoses (vascular dementia=17.2%, dementia=12.1%, schizophrenia and related disorders=21.5% and anxiety disorders=27.3%) (X2=36.3, p
    04/2007; DOI:10.5920/mhldrp.2007.4155


Available from